PPD
General Information | |
Business: |
We are a leading provider of drug development services to the biopharmaceutical industry, focused on helping our customers bring their new medicines to patients around the world. We have been in the drug development services business for more than 30 years, providing a comprehensive suite of clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. Over that time, we have developed a track record of consistent quality, delivery and continuous innovation that has enabled us to grow faster than our underlying market over the past five years and deliver strong financial results. |
Industry: | COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
Employees: | 23000 |
Founded: | 2017 |
Contact Information | |
Address | 929 North Front Street, Wilmington, NC 28401, US |
Phone Number | (910) 251-0081 |
Web Address | http://www.ppdi.com |
View Prospectus: | PPD |
Financial Information | |
Market Cap | $9164.5mil |
Revenues | $3962.8 mil (last 12 months) |
Net Income | $84.5 mil (last 12 months) |
IPO Profile | |
Symbol | PPD |
Exchange | NASDAQ |
Shares (millions): | 60.0 |
Price range | $27.00 - $27.00 |
Est. $ Volume | $1620.0 mil |
Manager / Joint Managers | Barclays/ J.P. Morgan/ Morgan Stanley/ Goldman Sachs/ BofA Securities/ Credit Suisse/ Jefferies/ UBS Investment Bank/ Citigroup/ Deutsche Bank Securities/ Evercore/ HSBC/ Mizuho Securities/ Baird/ William Blair |
CO-Managers | BofA Securities/ Credit Suisse/ Jefferies/ UBS Investment Bank/ Citigroup/ Deutsche Bank Securities/ Evercore/ HSBC/ Mizuho Securities/ Baird/ William Blair/ Drexel Hamilton |
Expected To Trade: | 2/6/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |